The Exosomes we use are an allogenic Wharton’s Jelly MSC-derived Exosome product, manufactured using proprietary isolation and purification technologies. The natural cell origin of Exosomes enables improved efficacy, biocompatibility, and reduced immunogenicity. ISO X has a growth factor characterization report for product cross-section and a nanocyte report for exosome count validation to ensure consistency and product quality. The Exosome Therapy we use has 75 Billion Exosomes per 5 ml vial, 15 Billion Exosomes per ml. ISO X is manufactured from umbilical cords from full-term deliveries. All donors are pre-screened and undergo comprehensive testing. The Exosomes we use provide full transparency and alia quality assurance through third-party assays demonstrating product cross-section. Exosome therapy is considered safe, particularly since this is a non-cellular therapy.Exosomes are cell ‘messengers’, not stem cells. Therefore, this type of therapy does not come with the risk of the patient’s body rejecting treatment. Exosome therapy is not yet FDA approved. However, our MSC Exosomes are collected and processed under strict guidelines in an FDA-approved Lab.